Hu, Mu, RtApplications:
WB, IHC, IP, ELISA(Cap)Host:
WB, IHC, CyTOF-ready, Flow, ICC/IFHost:
Applications: WB, IP
Applications: WB, IP
Effective inhibitors of matrix metalloproteinases (MMPs), a family of connective tissue-degrading enzymes, could be useful for the treatment of diseases such as cancer, multiple sclerosis, and arthritis (1). Matrix metalloproteinase-3 (MMP-3) is a protein involved in tumor invasion and metastasis. MMP3 (stromelysin) is a secreted metalloprotease with a wide range of substrate specificities. MMP3 is synthesized in a preproenzyme form with a calculated size of 54 kDa and a 17-amino acid long signal peptide. Data indicate that the expression and the possible involvement of secreted metalloproteases in tumorigenesis result from a specific interaction between the transforming factor and the target cell, which may vary in different species (2). In neural studies, matrix metalloproteinase-3 (MMP-3) was newly induced and activated in stressed dopamine cells, and the active form of MMP-3 (actMMP-3) was released into the medium. The released actMMP-3, as well as catalytically active recombinant MMP-3 (cMMP-3) led to microglial activation and superoxide generation in microglia and enhanced DA cell death. (3).
|Product By Gene ID
- EC 3.4.24
- EC 22.214.171.124
- Matrix metalloproteinase-3
- matrix metalloproteinase 3 (stromelysin 1, progelatinase)
- matrix metallopeptidase 3 (stromelysin 1, progelatinase)
Bioinformatics Tool for MMP-3
Discover related pathways, diseases and genes to MMP-3. Need help? Read the Bioinformatics Tool Guide
for instructions on using this tool.
Related MMP-3 Blog Posts
Check out the latest blog posts on MMP-3.
Read more MMP-3 related blogs.
|MMP3 - a potential target for arthritis therapies
Matrix metalloproteinases (MMPs) are responsible for the degradation of extracellular matrix proteins. MMPs are essential for tissue remodeling during normal processes such as embryonic development as well as pathological conditions such as arthri... Read more.